Abstract
Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.
| Original language | English |
|---|---|
| Pages (from-to) | 527-532 |
| Number of pages | 6 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 84 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1999 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Endocrinology, Diabetes and Metabolism
Cite this
Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. / Baldelli, Roberto; Ferretti, Elisabetta; Jaffrain-Rea, Marie Lise; Iacobellis, Gianluca; Minniti, Giuseppe; Caracciolo, Barbara; Moroni, Carlo; Cassone, Rosario; Gulino, Alberto; Tamburrano, Guido.
In: Journal of Clinical Endocrinology and Metabolism, Vol. 84, No. 2, 1999, p. 527-532.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients
AU - Baldelli, Roberto
AU - Ferretti, Elisabetta
AU - Jaffrain-Rea, Marie Lise
AU - Iacobellis, Gianluca
AU - Minniti, Giuseppe
AU - Caracciolo, Barbara
AU - Moroni, Carlo
AU - Cassone, Rosario
AU - Gulino, Alberto
AU - Tamburrano, Guido
PY - 1999
Y1 - 1999
N2 - Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.
AB - Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.
UR - http://www.scopus.com/inward/record.url?scp=0033054602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033054602&partnerID=8YFLogxK
U2 - 10.1210/jc.84.2.527
DO - 10.1210/jc.84.2.527
M3 - Article
C2 - 10022411
AN - SCOPUS:0033054602
VL - 84
SP - 527
EP - 532
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 2
ER -